IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes

In a recent interview with Applied Clinical Trials, Paul Shawah, EVP of Strategy at Veeva Systems, and Richard Staub, President of R&D Solutions at IQVIA, discussed their companies’ new global clinical and commercial partnership. Designed to simplify and accelerate clinical trials, the collaboration aims to maximize value for customers by integrating software, data, and services from both organizations. Early feedback has been overwhelmingly positive, underscoring the partnership’s potential to streamline workflows, enhance data quality, and support both traditional and decentralized clinical trial models, ultimately helping sponsors bring therapies to market faster.

ACT: What is the primary goal of the new global clinical and commercial partnerships between IQVIA and Veeva?

Shawah: The primary goal is customer success. That’s why we established a long-term agreement with IQVIA. After announcing the partnership this week, the feedback was overwhelmingly positive, which shows that customers recognize the value we’re bringing both in the near term and over the long term.

This is great news for customers because they want to use software, data, and services from both Veeva and IQVIA—and they want them to work seamlessly together. They want the process to be efficient and simple, and that’s exactly what this partnership delivers.

On the commercial side, the partnership enables the integration of data and software from both companies, allowing customers to choose solutions from either Veeva or IQVIA with ease. IQVIA has also joined our technology and services partner programs as an AI partner, which opens the door for their data to enhance some of our products, including AI-driven capabilities.

On the clinical side, as a CRO and clinical data partner, IQVIA can access all Veeva applications for running trials, including study builds with Veeva EDC. This integration aims to simplify workflows and accelerate processes for customers, making clinical and commercial operations more efficient than ever.

In short, the goal is to simplify and speed things up for customers while delivering long-term value.

Staub: I share Paul’s enthusiasm. What he describes is absolutely correct—this partnership represents a tremendous opportunity for our customers to leverage the capabilities of both organizations. From IQVIA’s perspective, we always take it a step further by focusing on the ultimate benefit: improving outcomes for patients. We’re excited about the partnership and what it means going forward.

Full Interview Summary: IQVIA and Veeva have launched a new global clinical and commercial partnership aimed at simplifying and accelerating clinical trials while maximizing value for customers. The primary goal of the collaboration is customer success—enabling clients to seamlessly access and use software, data, and services from both companies in an efficient, integrated manner. Early feedback on the partnership has been overwhelmingly positive, highlighting its potential to deliver both near-term and long-term benefits.

On the commercial side, the agreement allows customers to combine technologies from IQVIA and Veeva easily. IQVIA has joined Veeva’s technology and services partner programs as an AI partner, opening opportunities for its data to enhance Veeva products, including AI-driven applications. Clinically, IQVIA can leverage Veeva’s full suite of applications, such as Veeva EDC, to streamline study builds and trial execution. By combining the strengths of both organizations, the partnership aims to simplify workflows, improve compliance, and speed up data collection and cleaning, enabling sponsors to bring therapies to market faster.

The collaboration enhances clinical data management by integrating IQVIA’s CRO expertise with Veeva’s technology platforms. This “plug-and-play” approach allows trial sponsors to use the best-fit technologies for each study, improving efficiency and data quality. Sites benefit from user-friendly systems that encourage timely data entry, while sponsors gain faster access to clean, locked data for regulatory submission or progression to the next development phase.

Looking ahead, the partnership is positioned to support decentralized and hybrid trials, where technology interfaces directly with patients in addition to traditional sites. By combining operational expertise with advanced technology, IQVIA and Veeva aim to enable flexible, patient-centric studies that reduce timelines, improve research efficiency, and create new opportunities for innovation in clinical trial design.